PMC:7499532 / 155-1275
Annnotations
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 32-34 | Body_part | denotes | AG | http://purl.org/sig/ont/fma/fma61898 |
| T2 | 232-234 | Body_part | denotes | AG | http://purl.org/sig/ont/fma/fma61898 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T2 | 165-173 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T3 | 176-185 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T4 | 190-198 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T5 | 352-360 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T6 | 390-398 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T7 | 734-742 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T8 | 805-813 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T9 | 904-912 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T3 | 113-114 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T4 | 350-351 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T5 | 483-484 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T6 | 651-656 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T7 | 803-804 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
| T8 | 857-862 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
| T9 | 941-942 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | A |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 9 | 390-400 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 10 | 734-744 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 11 | 904-914 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 12 | 165-185 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
| 13 | 190-198 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 14 | 352-360 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 15 | 805-813 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T4 | 0-227 | Sentence | denotes | WHO convened an Advisory Group (AG) to consider the feasibility, potential value and limitations of establishing a closely-monitored challenge model of experimental SARS-CoV-2 infection and COVID-19 in healthy adult volunteers. |
| T5 | 228-307 | Sentence | denotes | The AG included experts in design, establishment and performance of challenges. |
| T6 | 308-802 | Sentence | denotes | This report summarizes issues that render a COVID-19 model daunting to establish (SARS-CoV-2’s potential to cause severe/fatal illness, its high transmissibility, and lack of a “rescue treatment” to prevent progression from mild/moderate to severe clinical illness) and it proffers prudent strategies for stepwise model development, challenge virus selection, guidelines for manufacturing challenge doses, and ways to contain SARS-CoV-2 and prevent transmission to household/community contacts. |
| T7 | 803-940 | Sentence | denotes | A COVID-19 model could demonstrate protection against virus shedding and/or illness induced by prior SARS-CoV-2 challenge or vaccination. |
| T8 | 941-1120 | Sentence | denotes | A limitation of the model is that vaccine efficacy in experimentally challenged healthy young adults cannot per se be extrapolated to predict efficacy in elderly/high-risk adults. |